Recently, Minhai Biotechnology was granted authorization by the National Intellectual Property Administration and designated as a practical training site for the “National Intellectual Property Administration Examiner Practice (Beijing Zhongguancun) Base.” The National Intellectual Property Administration’s Examiner Practice Base, recommended by the Zhongguancun Intellectual Property Promotion Center and approved by the National Intellectual Property Administration, enables participating enterprises and institutions to host professional technical training, research, and internship programs for examiners. By organizing such practical activities, it facilitates a precise alignment between the nation’s high-quality examination resources and the innovation-driven entities in Zhongguancun, thereby promoting the high‑quality development of corporate intellectual property.

8 month 8-12 On [date], an examiner from the Biologics Division of the Pharmaceutical and Biological Products Review Department of the National Intellectual Property Administration conducted a week-long “Patent Examiner Practical Training” at Minhai Bio. This marked the first time that Minhai Bio, as a designated practice site, has hosted such an activity for patent examiners. During the field‑based activities, patent examiners visited the company’s vaccine R&D center and production facilities, gaining insights into its vaccine development processes and manufacturing management. They also engaged in discussions and exchanges with the heads of various R&D projects and key technical personnel, focusing on topics such as the evolution of the vaccine industry, technological innovation, and critical aspects of patent filing and examination.

Patent examiners from the National Intellectual Property Administration visited enterprises to conduct practical activities, providing on‑site guidance and addressing the questions of Minhai Bio’s management and technical staff. This initiative established a robust communication platform, and through comprehensive, precise, and in‑depth dialogue, it further strengthened the company’s awareness of intellectual property strategy and patent protection.

Minhai Biotechnology has consistently placed great emphasis on technological innovation and intellectual property protection. Under the personal guidance and strong support of leaders including General Managers Du, Zheng, and Liu, the company has obtained authorized patents. 49 items, successively on 2014 In [year], it was recognized by the Beijing Municipal Intellectual Property Office as a “Beijing Municipal Intellectual Property Demonstration Unit.” 2016 In [year], it was recognized by the National Intellectual Property Administration as a “National Intellectual Property Advantage Enterprise.” 2018 In [year], the company obtained certification under the Intellectual Property Management System standard, and its intellectual property management capabilities have steadily improved.

Looking ahead, Minhai Biologics will fully leverage the Examiner Practice Base platform to strengthen communication, exchange, and collaborative discussions with China’s specialized review teams, while establishing long-term cooperative mechanisms. Upholding its corporate mission of “creating better vaccines to benefit human health,” the company will continue to drive innovation in vaccine technology, build up intellectual property assets, and develop more “Made in China” vaccines.   Contribute to the “global new” vaccine.